MedTrace Logo

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 616

Last updated 2026-03-09

No results posted yet for this study

Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.

The first four subprotocols include the following:

Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Conditions

  • Non-Small Cell Lung Cancer, NSCLC
  • KRAS, NRAS, HRAS-mutated NSCLC
  • KRAS G12C-mutated Solid Tumors, Lung Cancer
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
  • RAS G12D-mutated NSCLC

Interventions

DRUG

RMC-6291

Oral tablet

DRUG

RMC-6236

Oral tablet

DRUG

Pembrolizumab

IV Infusion

DRUG

Cisplatin

IV Infusion

DRUG

Carboplatin

IV Infusion

DRUG

Pemetrexed

IV infusion

DRUG

RMC-9805

Oral Tablet

Sponsors & Collaborators

  • Revolution Medicines, Inc.

    lead INDUSTRY

Principal Investigators

  • Revolution Medicines · Revolution Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-18
Primary Completion
2027-06-30
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06162221 on ClinicalTrials.gov